Activation of helper T cells results in coordinate expression of a number of cytokines involved in dierentiation, proliferation and activation of the haematopoietic system. Granulocyte-macrophage colony stimulating factor (GM ± CSF) is one such cytokine, whose increased expression results mostly from increases in transcription. Cis-acting elements with NFkB, AP1 and ETS-like binding motifs have been identi®ed in the promoter region of the GM ± CSF gene, and are important or essential for transcriptional activity following T cell activation. ETS1 is a transcription factor of the ETS family that is expressed in T cells. We have previously shown that ETS1 can transactivate GM ± CSF in Jurkat T cells, but only after the cells have been stimulated by treatment with PMA and ionomycin, agents that mimic T cell activation. Thus we proposed that ETS1, which is expressed constitutively in Jurkat cells, may act in concert with PMA/ionomycin inducible factors. Here we show that ETS1 can transactivate a GM ± CSF reporter construct in unstimulated Jurkat cells, providing that either NFkB or AP1 transcription factors are supplied by co-transfection. We con®rm that binding of endogenous NFkB and AP1 is induced following PMA/ionomycin treatment of T cells. Transactivation by ETS1, NFkB and AP1 is synergistic, and mutation of the individual binding sites reveals that the transcriptional activities of these factors are interdependent. Our results suggest that constitutive ETS1, and inducible NFkB and AP1, cooperate as part of a higher order transcriptional complex in activated T cells.
Introduction
Helper T cells are activated, and initiate an immune response, through recognition of speci®c antigens presented by antigen presenting cells. Activation is primarily mediated through the T cell receptor, which enhances intracellular calcium levels and protein kinase C (PKC) activity (Miyajima et al., 1988; Valge et al., 1988; Klausner and Samelson, 1991) . These events can be mimicked in culture by addition of the calcium ionophore, ionomycin and the protein kinase C activator, PMA (phorbol 12-myristate 13-acetate).
Activating signals ultimately result in cellular proliferation, and transcriptional induction and secretion of a number of cytokines including IL-2 (interleukin-2), IL-3, IFNg (interferon-gamma) and GM ± CSF (granulocytemacrophage colony-stimulating factor) (Stanley et al., 1985; Miyajima et al., 1988; Arai et al., 1990) . These cytokines direct the eector functions of various cell types involved in an immune response, including B cells, macrophages, mast cells, eosinophils and neutrophils.
GM ± CSF expression in activated T cells is regulated by two mechanisms. Firstly, GM ± CSF transcription is controlled by both constitutive and inducible transcription factors that interact with the proximal promoter (Sugimoto et al., 1990; KoyanoNakagawa et al., 1993; Masuda et al., 1993; Ye et al., 1996) and a distal enhancer shared by GM ± CSF and IL-3 Osborne et al., 1995) . Secondly, GM ± CSF mRNA stability is controlled through an AU rich 3' region (Shaw and Kamen, 1986; Iwai et al., 1993) , although the importance of this mechanism has been questioned (Brorson et al., 1991) . Essential elements in the proximal promoter (Figure 1 ) include the CLE2 (conserved lymphokine element)/GCbox region, which supports the binding of inducible NFkB/Rel and constitutive Sp1 family members, and CLE0, which binds inducible AP1 and constitutive ETS factors. An inducible NFAT-like complex (Masuda et al., 1993) also displays weak binding to CLE0. The CLE0 region has been described as a part of a triple repeat CATT(A/T) element by others (Nimer et al., 1990) . In addition, other factors have recently been shown to be involved in GM ± CSF transcriptional control. CBF (Core Binding Factor) (Takahashi et al., 1995; Cockerill et al., 1996) and YY1 (Yin-Yang 1) (Ye et al., 1994 (Ye et al., , 1996 appear to exert positive and negative eects, respectively, upon GM ± CSF transcription. These two factors bind a region between the CLE2 and CLE0 elements.
Previously we have characterised the binding of ETS1 and other ETS family members, to the ETS binding site within the CLE0 element of the GM ± CSF promoter (Thomas et al., 1995) . Our experiments suggested that ETS1 plays an important role in GM ± CSF transcription following PMA and ionomycin stimulation, and hence in T cell activation. However, we found that ETS1 binding appeared to be constitutive, and that ETS1 could not transactivate GM ± CSF unless the T cells were ®rst treated with PMA and ionomycin. These results suggest that: (1) ETS1 does not instigate GM ± CSF transcription and; (2) either ETS1 is modi®ed by PMA/ionomycin treatment or other factors induced by PMA/ionomy-cin are required. In this study we characterise requirements for ETS1 transactivation. We show that ETS1 can transactivate a GM ± CSF reporter construct in unstimulated Jurkat cells, providing that either or both NFkB and AP1 transcription factors are supplied exogenously. We con®rm previous studies that show binding of endogenous NFkB and AP1 is inducible following PMA/ionomycin treatment of T cells. Transactivation by ETS1, NFkB and AP1 is synergistic, and mutation of the individual binding sites reveals that the transcriptional activities of these factors are inter-dependent. Our results suggest that NFkB and AP1 may be additional co-factors required for ETS1 mediated transactivation, and that these three factors operate synergistically as part of a higher order transcriptional complex in activated T cells.
Results

ETS1 transactivation requires PMA and ionomycin stimulation or additional NFkB and/or AP1 factors
A CAT reporter construct containing 600 bp of the human GM ± CSF promoter (pGM600) (Figure 1 ) was transiently transfected into Jurkat cells, and the eects of co-transfected expression constructs and treatment of the cells with PMA and ionomycin were analysed ( Figure 2 , Table 1 ). The raw CAT data for pGM600, with the various treatment/co-transfections, was normalised to its basal expression, which was given the value of`one'. The mean of at least four replicates for each experiment was graphed to show a`fold induction' over basal pGM600 expression, to facilitate comparison between the dierent treatments/co-transfections.
Co-transfection of an ETS1 expression construct resulted in fourfold transactivation of the GM ± CSF reporter, but only if the cells were ®rst treated with PMA and ionomycin. Potentially, PMA/ionomycin either modi®es the ETS1 protein or supplies co-factors required for ETS1 transactivation. Because the GM ± CSF promoter contains binding sites for other transcription factors in close proximity to that of ETS1 (Figure 1 ), we examined transcriptional interactivity between ETS1, NFkB and AP1 factors. Transfection of NFkB (p50 and p65) and AP1 (c-Fos and c-Jun) resulted in 18-and ninefold transactivation, respectively, in unstimulated Jurkat cells (Figure 2 , Table 1 ). Although ETS1 alone could not produce transactivation in unstimulated cells, co-transfection of ETS1 with NFkB or AP1 resulted in strong synergistic transactivation. ETS1 and NFkB together resulted in increased GM ± CSF transcription 123-fold higher than basal expression ± sevenfold higher than NFkB alone. ETS1 and AP1 resulted in a 34-fold increase, which was fourfold higher than AP1 alone. NFkB and AP1 together were also strongly synergistic, resulting in a 308-fold increase in transcription compared with basal expression. Maximal synergistic transactivation was achieved with all three transcription factors, resulting in a 820-fold increase over basal expression. In this experiment, addition of ETS1 resulted in a 2.5-fold increase compared to just NFkB/AP1.
Thus, transactivation by ETS1 was possible in PMA/ionomycin treated cells or in unstimulated cells supplemented with exogenous NFkB and/or AP1 transcription factors, suggesting that these may be PMA/ionomycin induced co-factors required for ETS1 function. Consequently, we have examined whether DNA binding to ETS, NFkB and AP1 sites in the proximal GM ± CSF promoter (Figure 1 ) is increased upon stimulation of Jurkat cells. In addition, we wished to identify the NFkB and AP1 factors which may synergise with ETS1 in vivo.
ETS1 binds the GM ± CSF promoter constitutively EMSA (electrophoretic mobility shift assay) analysis showed that a number of proteins in Jurkat nuclear lysates bound to the GMETS sequence contained within CLE0, 735 to 744 of the GM ± CSF promoter (Figure 3 ± lanes 1 and 2). The complex labeled n/s appeared to represent a non-speci®c DNA binding protein capable of binding any oligonucleotide sequence. The complexes A, B and C were competed by an excess of a consensus ETS binding site (MSV) (lane 3) and by GMETS (lane 4). A mutant GMETS sequence (GMETSm1), which contains a point mutation in the core of the ETS binding site, was unable to compete for binding of these complexes (lane 5), and did not display binding to them when labeled and used as a probe (lane 7). Thus, all complexes display characteristics consistent with DNA binding proteins of the ETS family. Complex C was identi®ed as ETS1 by its speci®c removal with addition of an ETS1 antibody (lane 6) and the just visible appearance of a supershift (identi®ed by the open arrow). The identity of complexes A and B have not yet been determined, but could represent binding of other ETS family members expressed in T cells such as ETS2, GABPa and/or FLI1. Binding of another complex, above that of complex A, was also faintly visible (small arrow). Previously we have identi®ed this complex as Figure 1 Structure of the GM ± CSF promoter, CAT constructs and oligonucleotide sequences. The 600 bp human GM ± CSF promoter contains a transcriptional control region of approximately 100 bp proximal to transcriptional initiation (arrow). This region contains elements conserved among the promoters of genes expressed following T cell activation. The CLE2 (conserved lymphokine element)/GC-box region contains binding sites for the NFkB and Sp1 families of transcription factors. CLE0 contains binding sites for AP1 and ETS families. Other elements include a consensus TATA box, and binding regions for CBF (core binding factor) and YY1. The sequences of oligonucleotides spanning the NFkB, AP1 and ETS sites and their mutations are shown. Consensus binding site sequences are also shown. pGM600 is a CAT construct driven by the 600 bp wild-type GM ± CSF promoter. Mutant binding sites have been introduced into the pGM600-ETS1, -kB and -AP1 constructs, as indicated ELF1 (Thomas et al., 1995) , but cannot consistently detect it due to the low level of binding.
The ETS-like complexes (A, B and C) displayed strong binding to the GMETS site. Nuclear lysates from Jurkat cells treated for 4 h with PMA and ionomycin displayed little dierence in the qualitative or quantitative binding of these complexes (compare lanes 1 and 2). The cells were treated for 4 h with PMA/ionomycin since analysis of pGM600 induction over time suggested that the GM ± CSF promoter was maximally active at this time (data not shown). In addition, activation of cells following treatment with PMA/ionomycin was con®rmed by measurement of secreted interferon g in the media (data not shown). Hence ETS1 binding (as well as factors A and B) appears to be constitutive over the time frame of the experiment. This data supports the hypothesis that, although PMA/ionomycin treatment of T cells provides conditions under which ETS1 can transactivate GM ± CSF, PMA/ionomycin provides required ETS1 co-factors, rather than directing any modi®cation of ETS1 that might increase its binding anity.
NFkB p65/p50 and p50/p50 complexes bind the GM ± CSF promoter following PMA and ionomycin stimulation Two NFkB-like complexes in stimulated Jurkat nuclear lysates (complex A and B) bound the GMkB site contained within the CLE2/GC-box region, 777 to 785 of the GM ± CSF promoter ( Figure 4a ± lane 3). Both complexes were competed by an excess of a consensus NFkB sequence (lane 4) and by the GMkB oligonucleotide (lane 5), but not by mutant GMkB (GMkBm1) (lane 6). Additionally, labeled GMkBm1 did not bind these complexes when used as the probe (lane 8). The consensus NFkB probe bound most strongly to a complex in stimulated lysates that approximately co-migrated with complex A (lane 10), suggesting that they are equivalent. Binding of recombinant p50 to the GMkB site was correctly identi®ed as p50 using a panel of NFkB family antibodies ( Figure 4b ± lanes 2 ± 6). Since NFkB factors usually bind as dimers, this complex most probably represents a p50/p50 homodimer. In Jurkat nuclear extracts these antibodies identi®ed p50 in both complexes A and B (lane 10) and p65 in complex A (lane 11), suggesting that complex A represents a p50/ p65 heterodimer, and complex B a p50/p50 homodimer. Additionally, both recombinant p50/p50 and complex B had a similar migration rate, suggesting that they are equivalent. It appeared that neither IkB nor c-Rel, formed part of the nuclear NFkB complexes that bound GMkB, since the binding of complexes A and B were not aected by addition of antibodies to these proteins (lanes 8 and 9, respectively). 
ANTIBODY/ COMPETITOR
Figure 3 EMSA analysis of the ETS factors able to bind the GMETS sequence in Jurkat nuclear lysates. The labeled oligonucleotide (probe) is either GMETS or GMETSm1 (also referred to as m1). Protein samples were Jurkat (Jur) cell nuclear lysates, either untreated (7) or PMA/ionomycin treated (P+I). Antibodies or competitor oligonucleotides were added to binding reactions as indicated. aEts1 (E44) is an ETS1 speci®c monoclonal antibody. Three ETS-like factors able to bind GMETS are labeled complex ( Binding of the p50/p65 and p50/p50 complexes to GMkB were not detectable in unstimulated Jurkat nuclear lysates, but were strongly induced following treatment of the cells for 4 h with PMA and ionomycin (Figure 4a ± lanes 2 and 3). The consensus NFkB sequence did however display some binding to proteins in unstimulated lysates (lane 9), probably due to its very high anity compared to GMkB. These complexes displayed similar but slightly faster and slower migration rates compared to the p50/p65 complex bound to GMkB, and may represent binding of unidenti®ed NFkB family members.
AP1 complexes containing c-Fos and c-Jun, and other fos/jun family members, bind the GM ± CSF promoter following PMA and ionomycin stimulation AP1-like binding to the GMAP1 sequence contained within CLE0, 743 to 750 of the GM ± CSF promoter, was represented by a diuse band in Jurkat nuclear lysates ( Figure 5a ± lane 2). This complex was competed by an excess of a consensus AP1 sequence (lane 3) and by the GMAP1 oligonucleotide (lane 4), but not by mutant GMAP1 (GMAP1m1) (lane 5). Also, labeled GMAP1m1 did not bind this complex (lane 7), but the AP1 consensus site did (lane 9). The AP1 consensus site appears to bind much more strongly than GMAP1, and appeared to bind additional AP1-like complexes. Recombinant c-Fos and c-Jun, expressed together in COS cells, also produced a diuse band, in combination with AP1 factors already present in COS nuclear lysates ( Figure  5b ± lane 2). Cross-reacting antibodies to Fos (panFos: apfos) and Jun (pan-Jun: apjun) family members, demonstrated that most or all of the complexes present contained Fos/Jun family components (lanes 3 and 5). The c-Fos speci®c antibody appeared to remove just the top half of the band (lane 4). c-Jun was present in both upper and lower parts of the band (lane 6). Based on these results, it appears that binding was constituted by c-Fos/c-Jun heterodimers, c-Jun/c-Jun homodimers and other Fos/Jun family complexes. These experiments verify the ®delity of the antibodies. In Jurkat nuclear lysates, the diuse band appeared to contain multiple Fos/Jun family components (lanes 8 and 10). c-Fos was predominant in the upper part of the band (lane 9) and c-Jun in the lower (lane 11), although these two speci®c components also appeared to contribute to both upper and lower portions. So, although c-Fos/c-Jun heterodimers and c-Jun/c-Jun homodimers appeared to be present in the band, other Fos/Jun family dimers were also present. The diuse nature of the AP1 complex could be explained by the binding of multiple Fos/Jun family dimers of similar EMSA mobilities (Curran and Franza, 1988; Kerppola and Curran, 1995) , although the presence of multiple phosphorylated and non-phosphorylated species (Radler-Pohl et al., 1993; Woodgett et al., 1993) could also contribute to the diuse appearance of this band. The AP1 complexes were undetectable in unstimulated Jurkat nuclear lysates, but were induced after treatment of cells for 4 h with PMA/ionomycin ( Figure  5a ± lanes 1 and 2) . Although, using a stronger AP1 binding site like the AP1 consensus, AP1 complexes were detected at lower levels in lysates from unstimulated cells (lane 8). Similarly to NFkB binding, binding of AP1 complexes present in unstimulated Jurkat cells to the AP1 consensus displayed similar, but distinctly dierent mobilities, compared to those that bound GMAP1 in unstimulated cells.
Mutations of the ETS, NFkB and AP1 binding sites reduce GM ± CSF transcription in response to PMA and ionomycin, and to ETS1 transactivation after PMA/ ionomycin treatment To test whether the ability of ETS1 to transactivate in PMA/ionomycin stimulated cells may in fact be due to the induction of NFkB and/or AP1 factors, we have mutated the respective binding sites for these factors (Figure 1) , and examined the eects upon PMA/ ionomycin mediated GM ± CSF transcription, and ETS1 transactivation following PMA/ionomycin treatment. The modi®cations to pGM600 involve minimal point-mutations, analogous to those found in the mutant oligonucleotides GMETSm1, GMkBm1 and Figures 3, 4a and  5b) . Mutation of the ETS, NFkB or AP1 transcription factor binding sites in pGM600 resulted in very little change to the basal level of expression, which were not statistically signi®cant (1.2-, 1.5-and 1.4-fold higher than wild-type, respectively). The raw CAT data for each construct (pGM600, pGM600-ETSm1, pGM600-kBm1, pGM600-AP1m1), with the various treatment/ co-transfections, was normalised to its own basal expression, which was given the value of`one'. The mean of at least four replicates for each experiment was graphed to show a`fold induction' over basal expression, to facilitate comparison between the dierent mutations and treatment/co-transfections.
All of these mutations resulted in reduction or abolition of PMA/ionomycin responsiveness, suggesting that these regions of the promoter are important for GM ± CSF expression in activated T cells ( Figure 6 , Table 1 ). Mutation of the ETS site in CLE0 (pGM600-ETSm1) abolished PMA/ionomycin inducibility and also ETS1 transactivation following PMA/ionomycin treatment. Mutation of the NFkB site in the CLE2/ GC-box (pGM600-kBm1) and AP1 site in CLE0 (pGM600-AP1m1) resulted in 1.4-and 1.6-fold PMA/ ionomycin induction, respectively, which were not statistically dierent to basal expression. However, the mutations resulted in 35% and 40% of the pGM600 induction by PMA/ionomycin, respectively. In addition, the NFkB and AP1 mutations greatly reduced the ability of ETS1 to transactivate, supporting the proposal that the PMA/ionomycin dependence of ETS1 transactivation is in fact due to dependence on PMA/ionomycin inducible co-factors such as NFkB and AP1. Figure 6 CAT analysis of the eects of ETS1, NFkB and AP1 mutations of pGM600 on PMA/ionomycin induction and ETS1 transactivation with PMA/ionomycin. The structures of the mutant GM ± CSF promoter constructs are shown schematically, with the bar pattern used to represent each (inset). Relative CAT activities/fold induction were calculated from raw CAT data as described in Materials and methods. Other labels and procedures are as described in Figure 2 Synergistic cooperation between ETS, NFkB and AP1 is reduced by mutations in their binding sites Although ETS1 activity seems to be dependent upon the presence of other factors, the ability of NFkB and AP1 to transactivate may also be dependent on other constitutive factors, such as ETS1, that are already present in unstimulated Jurkat cells. To test the interdependence of the ETS1, NFkB and AP1 factors, and whether these factors act directly through their respective binding sites, we analysed ETS1, NFkB and AP1 transactivation, in unstimulated Jurkat cells, with the promoter constructs containing mutations of their binding sites (Figure 7 , Table 1 ).
Transactivation with NFkB was reduced by approximately 90%, from 18-to 1.9-fold, after the NFkB site has been mutated, and AP1 transactivation (8.8-fold) was abolished with an AP1 mutation, indicating that the eect of these factors, alone, is achieved mainly through direct interaction with the promoter. However, mutation of the ETS site reduced NFkB transactivation by 63%, to 6.6-fold (P=0.01), and blocked AP1 mediated transactivation completely, suggesting that exogenous NFkB and AP1 functionally interact with endogenous factor/s in Jurkat cells that bind the ETS site. Mutation of the ETS binding site also eliminated the ability of ETS1 to transactivate in the presence of either or both NFkB and AP1, indicating that ETS1 acts by binding directly to the GM ± CSF promoter at this site.
The synergistic transactivation displayed by ETS1 and NFkB together (123-fold) was reduced by 94%, to 7.3-fold, by mutation of the ETS binding site, and by 97%, to fourfold, by mutation of the NFkB binding site. These mutations did not however completely block transactivation, possibly because there is still residual binding to the mutated sites, although this is not supported by the EMSA data (Figures 3 ± lane 7 and 4 ± lane 8). Alternatively, an additional p65 binding site in the CK1 element Himes et al., 1996) , just upstream of the NFkB binding site of the CLE2/GC-box region, and an additional ETS1 binding Figure 7 CAT analysis of the eects of ETS1, NFkB and AP1 mutations of pGM600 on ETS1, NFkB and AP1 transactivational synergy. Jurkat cells were unstimulated. The structures of the mutant GM ± CSF promoter constructs are shown schematically, with the bar pattern used to represent each (inset). Relative CAT activities/fold induction were calculated from raw CAT data as described in Materials and methods. Other labels and procedures are as described in Figure 2 site approximately 7300 bp from the transcription initiation site (Thomas et al., 1995) , could have contributed to the remaining NFkB transactivation. The synergistic transactivation displayed by ETS1 and AP1 together (34-fold) was abolished by mutation of either the ETS or the AP1 binding sites. Because the ETS and AP1 binding sites are very close together in the GM ± CSF promoter, the respective mutations were evaluated by EMSA, which con®rmed that mutation in one binding site did not disrupt or modify binding to the other (data not shown). The strong synergy displayed by co-transfection of ETS1, NFkB and AP1 together (820-fold) was particularly dependent upon an intact AP1 site (reducing transactivation by 99%, to 6.5-fold, when mutated), and to a lesser extent the ETS and NFkB binding sites (reducing transactivation by 92%, to 64-fold and 88%, to 97-fold, respectively, upon mutation).
Taken together, the results from ETS NFkB and AP1 mutations of the GM ± CSF promoter suggest a high degree of transactivational interdependence between these factors. In addition, although NFkB and AP1 appear to have some ability to operate independently, these experiments suggest that there is interactivity with endogenous ETS1, or other ETS factors, that are expressed constitutively in unstimulated Jurkat cells (Figure 3 ).
Discussion
Helper T cells are intimately involved in mediating immune responses to pathogens and tumours. Recognition of antigens is followed by a process of T cell activation, which ultimately results in expression and secretion of cytokines that enhance the function of various eector cells of the immune system. The expression of these cytokines is primarily mediated through increased transcription factor activity and subsequent transcription. Initially, our study of GM ± CSF transcription in T cells (Thomas et al., 1995) suggested that ETS1, a constitutively expressed transcription factor, was required for GM ± CSF transcription following T cell activation. However, we observed that this factor could only transactivate GM ± CSF in T cells that had ®rst been activated by PMA/ionomycin treatment. In this paper we show that ETS1 can transactivate GM ± CSF in unstimulated cells, provided that NFkB or AP1 transcription factors are supplied. We con®rm previous studies which demonstrate that NFkB and AP1 factors are induced upon T cell activation, suggesting that these factors are the PMA/ionomycin induced co-factors required for ETS1 transactivation. In addition, transactivation with combinations of ETS1, NFkB and AP1 is highly synergistic and interdependent, suggesting that these factors interact as a higher order transcriptional complex in activated T cells.
Although ETS1 could not transactivate a GM ± CSF promoter reporter construct co-transfected into unstimulated Jurkat T cells, both NFkB (p50 and p65) and AP1 (c-Fos and c-Jun) could. However, cotransfection of ETS1 with either or both NFkB and AP1 resulted in additional, or synergistic, transactivation, which is similar to that achieved by cotransfection of ETS1 into cells treated with PMA and ionomycin. Additionally, mutations designed to eliminate binding of NFkB or AP1 reduced the ability of PMA/ionomycin to induce GM ± CSF transcription (as did an ETS mutation). These mutations also significantly reduced the ability of ETS1 to transactivate GM ± CSF in T cells stimulated with PMA and ionomycin. Binding of endogenous ETS1 in Jurkat T cells was constitutive, and NFkB and AP1 were induced, following PMA/ionomycin treatment (also discussed later). Together, these results suggest that; (1) constitutive ETS1 and induced NFkB and AP1 are necessary for PMA/ionomycin mediated GM ± CSF expression; (2) PMA/ionomycin induces co-factors required for ETS1 activity rather than directing any modi®cation of ETS1 and might increase its binding anity; and (3) that these factors are NFkB and/or AP1.
The concept that ETS1 may act only in coordination with transcriptional partners is supported by a recent study that has identi®ed a link between ETS1 transactivation of the TIMP-1 promoter and its requirement for the presence of AP1 (Logan et al., 1996) . Surprisingly, another recently published paper has found that the GM ± CSF promoter can be transactivated by ETS1 in unstimulated T cells (Nimer et al., 1996) , which con¯icts with the data presented here. Their study involved the use of a truncated promoter in which the NFkB, Sp1, CBF, and possibly AP1 and YY1 binding sites, of the fulllength promoter, are missing. Thus, although our results suggest that ETS1 requires other co-factors for transactivation, there may also be inhibitory mechanisms that operate through the full length promoter that prevent ETS1 from transactivating alone.
We have shown that at least three ETS-like factors in Jurkat nuclear lysates bound the ETS site of CLE0 in the proximal GM ± CSF promoter. These factors, including ETS1, displayed high levels of constitutive binding, before and after 4 h of PMA/ionomycin treatment. In a previous publication (Thomas et al., 1995) we have elaborated further upon ETS1 binding to this site and provide evidence to suggest that ETS1 speci®cally is required for GM ± CSF transcription following T cell stimulation with PMA/ionomycin. However, some controversy exists as to whether ETS1 can be involved in the transcription of genes induced by T cell activation since ETS1 mRNA and protein levels are reduced following activation signals Romano-Spica et al., 1995) . In addition, the binding activity of p51 ETS1 can be reduced by calcium dependent phosphorylation (Fisher et al., 1991; Rabault and Ghysdael, 1994) . In fact, it has been suggested that ETS1 can act as a repressor and contributes to IL-2 expression in activated T cells due to a consequent reduction in its binding (RomanoSpica et al., 1995) . We believe that the consequences of these considerations are allayed by the following points: (1) the reduction in ETS1 protein levels only occurs relatively late in the activation process, due to changes in de novo synthesis (Romano-Spica et al., 1995); (2) although phosphorylation occurs quickly (within 5 min), the alternatively spliced p42 ETS1 product, expressed in T cells, lacks this inhibitory phosphorylation domain Fisher et al., 1991) ; (3) other phosphorylation sites present in both forms of ETS1 have been linked to enhanced transactivator activity (Bradford et al., 1995; Yang et al., 1996) ; (4) inactivation of the ets1 gene in mice results in T cells that display severe proliferative defects in response to activating signals (Muthusamy et al., 1995) , which indicates that ETS1 is required for T cell activation. Thus several lines of evidence, including the data presented here, suggest that ETS1 can be involved in transcription of genes during T cell activation. Possibly, ETS1 function is attenuated late in T cell activation via negative feedback mechanisms.
Binding of NFkB and AP1 factors to their respective binding sites in CLE2/GC-box and CLE0 of the GM ± CSF promoter were undetectable in unstimulated Jurkat cells, but were strongly induced upon 4 h of PMA/ionomycin treatment. The induced NFkB complexes were identi®ed as p50/p50 homodimers and p50/ p65 heterodimers, and multiple AP1 complexes were constituted by Fos and Jun family members including cFos and c-Jun. It is likely that p50/p65 constitutes a transcriptionally active complex (Schmitz and Baeuerle, 1991) , and the dierent AP1 dimers may exhibit varying positive or negative transactivating properties (Deng and Karin, 1993) . Our results con®rm and extend the ®ndings of others who have analysed binding to the GMkB and GMAP1 sites (Boise et al., 1993; Himes et al., 1996) , and provide clues as to which NFkB and AP1 family members may synergise with ETS1 in vivo. NFkB complexes are normally sequestered in the cytoplasm as precursors or by binding IkB (Beg et al., 1992; Finco and Baldwin, 1995) , an association that is known to be disrupted by PKC/Ca 2+ mediated phosphorylation and proteolysis of IkB and p105 (the p50 precursor) (Israel, 1995; Li et al., 1995; Verma et al., 1995) . Phosphorylation of p50 also results in a higher level of DNA binding stability (Li et al., 1994) , and increased p105 transcription is mediated by PMA (Meyer et al., 1991; Cogswell et al., 1993) . All of these mechanisms are potentially involved in the induction of NFkB binding observed. The induction of AP1 binding by PMA and ionomycin was probably mediated by PKC/Ca 2+ dependent phosphorylation/ dephosphorylation and consequent increased binding anity (Boyle et al., 1991; Karin, 1995) , and by increased transcription of Fos/Jun family members (Makover et al., 1991; Rincon and Flavell, 1994; Janknecht, 1995) . Interestingly, both NFkB and AP1 binding would be expected to increase shortly after stimulation of the cells by PMA/ionomycin (Boyle et al., 1991; Li et al., 1994) , and, in the case of NFkB be inhibited thereafter by newly synthesized IkB (Finco and Baldwin, 1995) . The data presented here clearly show that both NFkB and AP1 binding activities remain high in cells treated with PMA/ionomycin for 4 h, a time point at which we estimated the GM ± CSF promoter was most active (data not shown). Gene disruption of members of the NFkB/Rel family in mice produces T cell defects; disrupted p50 results in T cells with decreased ability to proliferate in response to activation signals ; p65 inactivation is an embryonic lethal mutation, but does cause defects in GM ± CSF induction in cell lines (Beg et al., 1995b) ; and c-rel disruption results both in defects in T cell proliferation (Kontgen et al., 1995) and GM ± CSF transcription (Gerondakis et al., 1996) . Inactivation of IkB results in enhanced granulopoiesis (Beg et al., 1995a) , possibly caused by increased or constitutive expression of cytokines such as GM ± CSF. Gene disruption of c-jun in mice appears to have no eect upon T cell proliferation or activation , but c-fos activation results in dramatically reduced numbers of certain T cell sub-sets (Johnson et al., 1992; Wang et al., 1992) , although these results are not supported by others (Jain et al., 1994) . Similarly to ETS1 gene inactivation, these experiments have accentuated the importance of NFkB and AP1 in the events of T cell activation, although there may be some redundancy in function between the dierent AP1 family members.
Co-transfection with combinations of ETS1, NFkB and AP1 resulted in strongly synergistic transactivation of the GM ± CSF promoter in unstimulated cells. In all experiments, transactivation was either greatly reduced or abolished by mutation of any of the ETS, NFkB or AP1 binding sites. These results demonstrate that ETS1, NFkB and AP1 transcription factors primarily mediate transactivation through direct interaction with their binding sites, but also require the binding of adjacent factors. Even transactivation by NFkB and AP1 alone were also shown to involve the ETS binding site, possibly by interacting with constitutive ETS1, or another endogenous ETS family member. Thus, a complex, interdependent, interaction between ETS1, NFkB and AP1 factors appears to play a role in controlling GM ± CSF transcription. Cooperative synergism between ETS1 and AP1 has been demonstrated previously with other promoters (Wasylyk et al., 1990; Majerus et al., 1992) , and AP1 and NFkB are known to synergise in transcriptional activation of the GM ± CSF promoter . Our data shows that ETS1 and NFkB also exhibit transcriptional synergy. The relationship between these three factors may in part be explained by ®ndings that ETS proteins can physically associate with AP1 in activated T cells (Bassuk and Leiden, 1995) , a process required for transcription involving ETS/AP1 enhancers. Also, p65 associates with c-Fos and c-Jun (Stein et al., 1993) , and, our preliminary data suggests, also with ETS1 (data not shown). Additionally, these factors can cooperate and potentially associate with other constitutive factors that bind the proximal GM ± CSF promoter, such as Sp1 (Gegonne et al., 1993; Masuda et al., 1994; Perkins et al., 1994; Ye et al., 1996) , CBF (Wotton et al., 1994) and perhaps YY1 (Ye et al., 1994) . Direct promoter association of ETS1, NFkB, AP1 and other factors, as well as with each other, potentially comprises a higher order transcriptional complex capable of mediating high levels of GM ± CSF transcription. We do not yet know the mechanism by which such synergy is accomplished, but could involve increased binding anity and/or decreased degradation of the combined factors, formation of binding surfaces for additional factors or components of the transcriptional machinery, and/or local conformational changes in the DNA. Support for any of these models of cooperativity is preliminary. However, some clues exist, such as the ability of p65 to functionally interact with TATA binding protein and TFIIB, components of the basic transcriptional machinery (Schmitz et al., 1995) , and the proposed abilities of NFkB and AP1 to induce bending of DNA upon binding (Kerppola and Curran, 1991; Pazin et al., 1996) . It seems likely that further study of the GM ± CSF promoter will describe a very complex set of interactive transcriptional control mechanisms.
Materials and methods
Cell lines and culture
Jurkat cells, a human leukemic T cell line, were grown in RPMI 1640 supplemented with 10% fetal calf serum, 100 U/ml penicillin and 100 mg/ml streptomycin. Monkey COS7 cells were grown in DMEM supplemented with fetal calf serum, penicillin and streptomycin as above. Both cell lines were maintained in a humidi®ed incubator at 378C in 5% CO 2 .
Plasmid constructs for transfection pGM600 contains approximately 600 bp of sequence preceding the transcription initiation site of the human GM ± CSF promoter. An EcoRI ± HindIII fragment from pHGM0.6 (Cockerill et al., 1993) containing the promoter was inserted upstream of the CAT reporter gene in pCAT-BASIC (Promega). pGM600-ETSm1, pGM600-kBm1 and pGM600-AP1m1 contain mutations in the ETS, NFkB and AP1 binding sites analogous to those found in the oligonucleotides ETSm1, kBm1 and AP1m1, respectively. Mutations of the GM ± CSF promoter were produced by PCR of pGM600 using oligonucleotides containing the respective mutations. The resulting PCR products were substituted back into pGM600. The ETS1, c-Fos and c-Jun expression constructs are based on the pEFBOS expression vector (Mizushima and Nagata, 1990) . The human ets1 cDNA from pGEM7HE-1 (Watson et al., 1988) was subcloned as a blunt KpnI ± HindIII fragment into the blunt-ended XbaI cloning site of pEFBOS. Human c-fos and mouse c-jun cDNAs (gifts of Jane Visvader, Walter and Eliza Hall Institute of Medical Research) were blunt cloned into pEFBOS. p50 (ApaI insert) and p65 (NotI insert) NFkB subunit cDNAs were ligated into the pRC/ CMV (Invitrogen) expression vector (Dunn et al., 1994) . The integrity of all constructs was con®rmed by sequence analysis.
Transfection of Jurkat cells and chloramphenicol acetyltransferase (CAT) assays
Jurkat cells were transfected with 10 mg CAT reporter plasmid and 6 mg of expression constructs as previously described (Thomas et al., 1995) . PMA (50 ng/ml) and ionomycin (500 ng/ml) was added to the growth media 24 h following transfection, where appropriate. Cells were harvested a further 24 h later and processed for CAT assays as previously described (Thomas et al., 1995) . The raw CAT data for each construct (pGM600, pGM600-ETSm1, pGM600-kBm1, pGM600-AP1m1), with the various treatment/co-transfections, was normalised to its own basal expression, which was given the value of`one'. The mean, and standard error of the mean (s.e.m.), of at least four replicates for each experiment was graphed to show a`fold induction' over basal expression, to facilitate comparison between the dierent mutations and treatments/co-transfections. Data were subjected to statistical analysis using unpaired t-tests, with resultant P values less than 0.05 considered signi®cant.
Electrophoretic mobility shift assays (EMSA)
Recombinant p50, c-Fos and c-Jun were produced by transient transfection of the respective expression vectors into COS cells. Sub-con¯uent cells were trypsinized, washed in growth medium (as above), and resuspended in PBS with 20 mM HEPES at 5610 6 cells/ml. Threehundred ml of cells were mixed with 20 mg DNA in 0.4 cm gap electroporation cuvettes and pulsed at 170 V and 500 mF (Biorad Gene Pulsar). Cells were replated into 10 cm petri dishes and harvested 24 h later. Jurkat cells were grown to 5610 5 cells/ml and were untreated or treated with PMA (50 ng/ml) and ionomycin (500 ng/ml) for 4 h prior to harvest. Nuclear lysates from COS and Jurkat cells were prepared as previously described (Thomas et al., 1995) . DNA binding experiments with nuclear lysates were performed using EMSA, as previously described (Thomas et al., 1995) . Brie¯y, puri®ed double stranded oligonucleotides were labeled with [a-32 P]dATP by Klenow ®ll-in reaction. One ng oligonucleotide probe was incubated for 10 min with 2 mg protein in DNA binding buer (1 mM EDTA, 10 mM Tris.Cl pH 8.0, 50 mM NaCl, 5 mM MgCl 2 , 5 mM dithiothreitol (DTT), 1 mg/ml BSA, 500 ng/ml poly-d(I-C).d(I-C), 500 ng/ml poly-dI.dC, 200 ng/ml sheared salmon sperm DNA), +100 ng unlabeled competitor oligonucleotides, +antibodies, in 10 ml ®nal volume. Assays were run through non-denaturing, 7% acrylamide (29 acrylamide : 1 bis-acrylamide), 0.56TBE gels, until free oligonucleotides had run o the bottom of the gel, to maximise separation of complexes.
Oligonucleotide sequences (shown in double stranded conformation) Antibodies for EMSA analysis ETS antibody; aEts1 ± monoclonal E44. NFkB antibodies; aIkB ± polyclonal KD21/1 (gift of Steve Gerondakis, Walter and Eliza Hall Institute of Medical Research), aRel ± monoclonal a497, ap50 ± monoclonal SC114 (Santa Cruz), and ap65 ± monoclonal SC109 (Santa Cruz). AP1 antibodies; aPFos ± polyclonal 'M' (pan-Fos cross-reacts with Fos family members), aPJun ± polyclonal (pan-Jun cross-reacts with Jun family members) (gifts of Donna R Cohen, Australian National University), acFos ± c-Fos polyclonal SC52 (Santa Cruz), and acJun ± c-Jun polyclonal SC45 (Santa Cruz).
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